secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001641172-25-003603
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma files provisional patent for PSMA-targeted PARP inhibitor conjugates for prostate cancer therapy
--------------------------------------------------------------------------------

- Filed provisional patent for PSMA-targeted PARP inhibitor conjugates, co-invented by Dr. Alan Kozikowski who contributed to Pylarify and Pluvicto.
- Theranostic molecule aims to preferentially target prostate cancer cells, enhancing radiation and chemotherapy effects.
- Global PSMA PET Imaging Market was $1.5B in 2022, expected to reach $2.0B by 2030; Pluvicto market predicted at $2B.
- Shuttle Diagnostics subsidiary focuses on PSMA-B ligand and PC-Rad test for predicting RT outcomes in localized prostate cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000164117225003603/0001641172-25-003603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000164117225003603/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-003603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer